NDA 022150 · Takeda Pharms USA
Firazyr
Icatibant Acetate · Subcutaneous
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jan 19, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Aug 25, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
26
11 Phase 3, 0 recruiting
FAERS reports
6,011
4,052 serious, 155 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 7, 2025.
FIRAZYR ® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. FIRAZYR is a bradykinin B2 receptor antagonist indicated for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. ( 1 )
Mechanism: Icatibant is a competitive antagonist selective for the bradykinin B2 receptor, with an affinity similar to bradykinin. Hereditary angioedema is caused by an absence or dysfunction of C1-esterase-inhibitor, a key regulator of the Factor XII/kallikrein proteolytic cascade that leads to bradykinin production. Bradykinin is a vasodilator which is thought to be responsible for the characteristic HAE symptoms of localized swelling, inflammation, and pain. Icatibant inhibits bradykinin from binding the B2 receptor and thereby treats the clinical symptoms of an acute, episodic attack of HAE.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 25, 2011 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanReviewLabelLetter
1 products under this application
- FIRAZYR · ICATIBANT ACETATE EQ 30MG BASE/3ML (EQ 10MG BASE/ML) · INJECTABLE, SUBCUTANEOUS · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Icatibant" as an intervention, any sponsor and status, largest first.
- I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill PatientsPivotal-lookingActive, not recruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT04488081 · 1,500 participants (planned) · Start Jul 31, 2020 · Primary completion Jul 31, 2028
Drug: Remdesivir; Imatinib Mesylate and 12 more · For: COVID-19
Sites: Birmingham, Alabama; Davis, California; Irvine, California · 36 sites in all
- Efficacy and Safety Study of Intra-articular Multiple Doses of Icatibant in Patients With Painful Knee OsteoarthritisPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00303056 · 590 participants · Start Feb 2006 · Primary completion Jul 2007
Drug: HOE140 Icatibant · For: Joint Disease
Sites: Bridgewater, New Jersey; Vienna, Austria; Prague, Czechia · 5 sites in all
- EASSI - Evaluation of the Safety of Self-Administration With IcatibantPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00997204 · 151 participants · Start Sep 25, 2009 · Primary completion Jun 22, 2011
Drug: Icatibant · For: Hereditary Angioedema
Sites: Buenos Aires, Argentina; Graz, Austria; Odense, Denmark · 26 sites in all
- Bradykinin Receptor Antagonism During Cardiopulmonary BypassPivotal-lookingCompleted
Vanderbilt UniversityAcademic, hospital or other
NCT00223704 · 150 participants · Start May 2006 · Primary completion Jun 2012
Drug: HOE 140; Aminocaproic Acid and 1 more · For: Cardiopulmonary Bypass; Inflammation; Fibrinolysis and 1 more
Sites: Nashville, Tennessee · 2 sites in all
- Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced AngioedemaPivotal-lookingCompleted
ShireTakeda (TAK)
NCT01919801 · 118 participants · Start Dec 2, 2013 · Primary completion Aug 22, 2015
Drug: Icatibant; Placebo · For: Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Sites: La Jolla, California; Washington D.C., District of Columbia; Gainesville, Florida · 55 sites in all
- A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00912093 · 98 participants · Start Jul 16, 2009 · Primary completion Oct 1, 2010
Drug: Icatibant; Placebo · For: Hereditary Angioedema
Sites: Alabaster, Alabama; Birmingham, Alabama; Scottsdale, Arizona · 64 sites in all
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)Pivotal-lookingCompleted
ShireTakeda (TAK)
NCT00500656 · 85 participants · Start Mar 1, 2005 · Primary completion Jul 25, 2006
Drug: Icatibant; Tranexamic Acid and 2 more · For: Hereditary Angioedema
Sites: Milan, Italy
- Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary AngioedemaPivotal-lookingCompleted
ShireTakeda (TAK)
NCT00097695 · 84 participants · Start Dec 28, 2004 · Primary completion Jul 17, 2006
Drug: Icatibant; Placebo · For: Angioedema
Sites: Washington D.C., District of Columbia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hereditary angioedema2,634
- drug ineffective504
- product dose omission issue451
- weight decreased415
- weight increased379
- injection site pain307
- off label use277
- product use issue275
- inappropriate schedule of product administration243
- headache234
- stress217
- condition aggravated203
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 46 |
| 2013 | 219 |
| 2014 | 215 |
| 2015 | 384 |
| 2016 | 400 |
| 2017 | 296 |
| 2018 | 622 |
| 2019 | 586 |
| 2020 | 406 |
| 2021 | 422 |
| 2022 | 456 |
| 2023 | 504 |
| 2024 | 442 |
| 2025 | 503 |
| 2026 | 505 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Firazyr (Icatibant Acetate)
2024 spending
$43.7M
Beneficiaries
170
719 claims
Per beneficiary
$257,140
$3,553.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $72,629,982 |
| 2021 | $61,220,572 |
| 2022 | $61,586,152 |
| 2023 | $56,351,521 |
| 2024 | $43,713,829 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy of Treatment of Non-hereditary Angioedema.
van den Elzen M, Go MFCL, Knulst AC, et al. · Clin Rev Allergy Immunol 2018 · Systematic Review
- Bradykinin B2 receptor blockade and intradialytic hypotension.
Gamboa JL, Mambungu CA, Clagett AR, et al. · BMC Nephrol 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Safety, efficacy, and pharmacokinetics of icatibant treatment in Japanese pediatric patients with hereditary angioedema: A phase 3, open-label study.
Hide M, Wang Y, Dote N, et al. · J Dermatol 2023 · Clinical Trial, Phase III
- A randomized trial of icatibant in ACE-inhibitor-induced angioedema.
Baş M, Greve J, Stelter K, et al. · N Engl J Med 2015 · Clinical Trial, Phase II, Comparative Study
- Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema.
Sinert R, Levy P, Bernstein JA, et al. · J Allergy Clin Immunol Pract 2017 · Multicenter Study, Randomized Controlled Trial
- Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.
Cicardi M, Banerji A, Bracho F, et al. · N Engl J Med 2010 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Takeda
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.